Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2024 07:00 ET | Source: ProKidney

ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

Reported interim REGEN-007 data that demonstrate rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT 2...
June 17, 2024 07:00 ET | Source: ProKidney

ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option

WINSTON-SALEM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic...
June 11, 2024 21:35 ET | Source: ProKidney

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic...
June 10, 2024 16:15 ET | Source: ProKidney

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic...
June 10, 2024 06:30 ET | Source: ProKidney

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both...
May 29, 2024 07:00 ET | Source: ProKidney

ProKidney to Participate in the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
May 21, 2024 07:00 ET | Source: ProKidney

ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024

WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic...
May 10, 2024 07:00 ET | Source: ProKidney

ProKidney Reports Business Updates and First Quarter 2024 Financial Results

Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a...
March 25, 2024 06:05 ET | Source: ProKidney

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in...
March 21, 2024 19:49 ET | Source: ProKidney

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic...